Equities

Yabao Pharmaceutical Group Co Ltd

600351:SHH

Yabao Pharmaceutical Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)5.27
  • Today's Change-0.04 / -0.75%
  • Shares traded4.93m
  • 1 Year change-35.97%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments565642457
Total Receivables, Net637787760
Total Inventory442449521
Prepaid expenses575039
Other current assets, total522620
Total current assets1,7531,9541,797
Property, plant & equipment, net1,3101,3801,457
Goodwill, net262675
Intangibles, net306334303
Long term investments418390361
Note receivable - long term------
Other long term assets------
Total assets3,8544,1314,077
LIABILITIES
Accounts payable163189141
Accrued expenses9310691
Notes payable/short-term debt268426522
Current portion long-term debt/capital leases5.41244.86
Other current liabilities, total256295247
Total current liabilities7851,0411,005
Total long term debt3.377.1032
Total debt277457558
Deferred income tax9.269.9511
Minority interest173737
Other liabilities, total626765
Total liabilities8771,1611,150
SHAREHOLDERS EQUITY
Common stock770770770
Additional paid-in capital955955955
Retained earnings (accumulated deficit)1,4261,2651,222
Treasury stock - common(150)----
Unrealized gain (loss)(24)----
Other equity, total--(20)(20)
Total equity2,9762,9702,927
Total liabilities & shareholders' equity3,8544,1314,077
Total common shares outstanding720770770
Treasury shares - common primary issue5000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.